Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Counseling breast cancer survivors on breastfeeding

Eva Blondeaux • 14 Sep 2024
ESMO 2024
Breast Cancer

Eva Blondeaux, MD, University of Genova, Genova, Italy, highlights the importance of individualized counseling for breast cancer survivors who wish to breastfeed. Whilst breastfeeding is generally safe for survivors based on evidence from a trial (NCT03673306) evaluating breastfeeding in patients with breast cancer, it is a deeply personal decision. Counseling should consider each woman’s willingness to breastfeed alongside the risk of cancer recurrence. Thus, with the lack of data on appropriate surveillance protocols during breastfeeding, there is a stressing need for careful, patient-centered approaches in these cases. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Blondeaux

Risk-reducing surgeries and survival in young BRCA carriers with breast cancer
4:04
Risk-reducing surgeries and survival in young BRCA carriers with breast cancer
Eva Blondeaux • 9 May 2025
Evaluating breastfeeding feasibility after breast cancer in BRCA carriers
0:56
Evaluating breastfeeding feasibility after breast cancer in BRCA carriers
Eva Blondeaux • 14 Sep 2024
Is breastfeeding after breast cancer safe and feasible?
0:49
Is breastfeeding after breast cancer safe and feasible?
Eva Blondeaux • 14 Sep 2024
Lifestyle and pregnancy factors impacting breastfeeding in breast cancer survivors
0:44
Lifestyle and pregnancy factors impacting breastfeeding in breast cancer survivors
Eva Blondeaux • 14 Sep 2024

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals